Insider Transactions in Q2 2022 at Kymera Therapeutics, Inc. (KYMR)
Insider Transaction List (Q2 2022)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
May 27
2022
|
Bvf Partners L P Director |
BUY
Open market or private purchase
|
Direct |
65,369
+1.53%
|
$915,166
$14.78 P/Share
|
|
May 26
2022
|
Bvf Partners L P Director |
BUY
Open market or private purchase
|
Direct |
224,057
+5.07%
|
$3,136,798
$14.21 P/Share
|
|
May 20
2022
|
Bvf Partners L P Director |
BUY
Open market or private purchase
|
Direct |
10,100
+0.19%
|
$141,400
$14.0 P/Share
|
|
May 06
2022
|
Bvf Partners L P Director |
BUY
Open market or private purchase
|
Direct |
100,000
+2.38%
|
$1,900,000
$19.25 P/Share
|
|
May 05
2022
|
Bvf Partners L P Director |
BUY
Open market or private purchase
|
Direct |
150,000
+3.38%
|
$2,850,000
$19.6 P/Share
|
|
May 04
2022
|
Jared Gollob Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
20,000
+16.15%
|
$20,000
$1.7 P/Share
|
|
May 03
2022
|
Bruce N. Jacobs Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
20,000
+24.75%
|
$40,000
$2.08 P/Share
|
|
May 03
2022
|
Nello Mainolfi Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
20,000
+3.83%
|
$40,000
$2.08 P/Share
|